InvestorsObserver
Sign Up Login

GENE Genetic Technologies Ltd

$2.25 $-0.14 (-5.86%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

GENE Stock Analysis Overview

What this means: Genetic Technologies Ltd (GENE) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives GENE a rank of 14. Our methodology considers analysis of the company's financial situation and how it has traded recently. GENE rank of 14 means that it ranks below 86% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

GENE Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

GENE Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

GENE Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

GENE Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

GENE Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

GENE Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

GENE Stock Analysis Overview

What this means: Genetic Technologies Ltd (GENE) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives GENE a rank of 14. Our methodology considers analysis of the company's financial situation and how it has traded recently. GENE rank of 14 means that it ranks below 86% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full GENE report

GENE Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

GENE Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

GENE Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

GENE Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

GENE Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

GENE Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Genetic Technologies Ltd (GENE) Analyst Forecast

GENE Price, Volume, Earnings, and Dividend Date

  • Last Price $2.25
  • Previous Close $2.39
  • Change $-0.14
  • Open $2.42
  • Volume 28,026
  • Avg. Volume (100-day) 31,954
  • Market Cap 8,656,243
  • Days Range 2.12 - 2.4571
  • 52-week Range 1.8 - 5.9
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date —
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Avg. Analyst Rec. Premium
  • Beta 1.291
  • PEG Ratio —

Genetic Technologies Ltd (GENE) Company Description

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States.

Genetic Technologies Ltd (GENE) Stock Chart

View Interactive GENE chart

My Watchlists

Top Stocks in Diagnostics & Research